SAD/MAD Study of FP-025 in Healthy Male Subjects

Phase 1, randomised, double-blind trial of aderamastat in asthma and chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Foresee Pharmaceuticals. Primary endpoints: Single ascending dose (SAD): Safety and tolerability of FP-025 at 9 days and Multiple ascending dose (MAD): Safety and tolerability of FP-025 at 13 days. Started Jun 2015; status: completed.